Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | ELOVL1 | Q9BW60 | 5/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357515 | 0.79 | ABL1 (0.58) | ABL1SIGMAR1ELOVL1UBE2MDCUN1D1 | |
| Oxalic Acid SCHEMBL1356980 | 0.77 | ABL1 (0.56) | ABL1SIGMAR1ELOVL1UBE2MDCUN1D1 | |
| SCHEMBL1899226 | 0.76 | SIGMAR1 (0.65) | SIGMAR1ATMKCNH2 | |
| SCHEMBL17965439 | 0.71 | ABL1 (0.60) | ABL1SIGMAR1ELOVL1CACNA1GCACNA1H | |
| Oxalic Acid SCHEMBL1356977 | 0.69 | ABL1 (0.58) | ABL1SIGMAR1ELOVL1CACNA1GCACNA1H | |
| SCHEMBL1357656 | 0.69 | ABL1 (0.73) | ABL1SIGMAR1ELOVL1MAPTTSHR | |
| SCHEMBL20608293 | 0.68 | SIGMAR1 (0.71) | SIGMAR1KCNH2 | |
| SCHEMBL1356743 | 0.68 | ABL1 (0.65) | ABL1SIGMAR1ELOVL1CACNA1GCACNA1H | |
| Oxalic Acid SCHEMBL1899223 | 0.67 | SIGMAR1 (0.91) | SIGMAR1MAPTATMKCNH2 | |
| SCHEMBL24685633 | 0.67 | ABL1 (0.66) | ABL1SIGMAR1ELOVL1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | ABL1 452/4885SIGMAR1 1/4885ELOVL1 3352/4885 |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | ABL1 452/4885SIGMAR1 1/4885ELOVL1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.